Clinical management of advanced gastric cancer: The role of new molecular drugs

doi:10.3748/wjg.v20.i40.14537

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 40

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12060)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

762

WORD

363

HTML

7882

Tables (1-5)

212

Sum=9219

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1531

Download

1310

Sum=2841

Oct 28, 2014 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (35)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 28, 2014; 20(40): 14537-14558
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14537

Table 3 Phase II/III trials of anti-epidermal growth factor receptor agents for advanced gastric cancer and gastro-esophageal junction cancer

Trial	Phase	Setting	Regimen	Patients (n)	RR	OS (mo)	TTP (mo)
FOLCETUX[187], 2007	II	1^st line	FOLFIRI + Cet	38	44.1%	16.0	8.0
NCT00477711[188], 2008	II	1^st line	CX + Cet	54	48.1%	-	5.23
DOCETUX[95], 2009	II	1^st line	C + TXT + Cet	72	41.2%	9.0	5.0
AIO[93], 2010	II	1^st line	FUFOX + Cet	52	65.0%	9.5	7.6
NCT01123811[94], 2011	II	1^st line	FOLFIRI + Cet	49	46.0%	16.5	90.0
NCT00398398[189], 2011	II	1^st line	XELOX + Cet	44	52.3%	11.8	6.5
NCT00517829[96], 2013	II	1^st line	DOCOX	75	26.5%	8.5	-
NCT00517829[96], 2013	II	1^st line	DOCOX + Cet	75	38.0%	9.4	-
EXPAND[97], 2013	III	1^st line	CX + Cet	455	29.0%	9.4	4.4
			CX	449	30.0%	10.7	5.6
REAL-III[103], 2013	II-III	1^st line	EOX + P	278	42.0%	8.8	6.0
			EOX	275	46.0%	11.3	7.4
NCT00113581[107], 2008	I	1^st line	ECX + M	21	65.0%	-	5.2
MATRIX[190], 2010	II	1^st line	ECX + M	35	58.0%	12.2	7.1
MATRIX[190], 2010	II	1^st line	ECX	35	31.0%	9.4	4.8
NCT01813253[111], 2011	II	2^nd line	Iri	82	18.4%	7.5%	85 d
NCT01813253[111], 2011	II	2^nd line	Iri + N	82	10.3%	9.7%	73 d

Cet: Cetuximab; C: Cisplatin; TXT: Docetaxel; X: Capecitabine; E: Epirubicin; O: Oxaliplatin; P: Panituimumab; E: Epirubicin; Iri: Irinotecan; M: Matuzumab; N: Nimotuzumab; FOLFIRI: 5 fluorouracil plus folinic acid plus irinotecan; FUFOX: 5 fluorouracil plus oxaliplatin; DOCOX: Docetaxel plus oxaliplatin; XELOX: Capecitabine plus oxaliplatin; RR: Response rate; OS: Overall survival; TTP: Time to progression.

Citation: Vita FD, Martino ND, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M. Clinical management of advanced gastric cancer: The role of new molecular drugs. World J Gastroenterol 2014; 20(40): 14537-14558
URL: https://www.wjgnet.com/1007-9327/full/v20/i40/14537.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i40.14537